ClinicalTrials.gg
Enrolling by invitationNCT06896110Updated Oct 27, 2026

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

A Phase 1 interventional study of Nivolumab and Azacitidine (AZA) in Glioblastoma (GBM), Diffuse Midline Glioma (DMG) and Astrocytoma, IDH-Mutant, Grade 4, sponsored by Andrew P. Groves. Enrolling by invitation at 1 site in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Andrew P. Groves · Phase 1, Interventional, and Treatment

How we know · 5 judgments

Updated Oct 27, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing nivolumab in Glioblastoma — 3 open to participants now, 11 under way, none of them phase 3. Nivolumab · Glioblastoma.

Planned enrollment
11th of 20
34 · median 36
Started
2025
with 1 other
Phase 1
6 of 20
1 open now
Primary completion
2028-03
later than 7 of 10 live
Registered
20th of 20
by date
Lead sponsor
1 of 20
Andrew P. Groves

Among the 20 studies testing nivolumab in Glioblastoma, this one is the 11th largest by planned enrollment, is one of 2 that started in 2025, is one of 6 in phase 1, reaches primary completion later than 7 of the 10 other live ones, and was the 20th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

3 of the 20 studies testing nivolumab in Glioblastoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing nivolumab in Glioblastoma, or all of them as a file.
02

Study summary

This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.

Read the detailed description

PRIMARY OUTCOME Phase I To determine the safety and maximum tolerated dose (MTD) of intrathecal (IT) azacitidine in combination with IT nivolumab in patients with recurrent high-grade glioma

Expansion Cohort To estimate the overall response rate (ORR)

SECONDARY OUTCOMES

To estimate:

  1. Duration of response (DOR)
  2. Progression-free survival (PFS)
  3. Overall survival (OS)

EXPLORATORY OUTCOMES Changes in immune profiling (flow cytometry, cytokine/chemokine analysis) and circulating tumor DNA (ctDNA) biomarkers (quantification, DNA methylation)

03

Conditions studied

  • Glioblastoma (GBM)
  • Diffuse Midline Glioma (DMG)
  • Astrocytoma, IDH-Mutant, Grade 4
  • Diffuse Hemispheric Glioma, H3 G34-Mutant
  • Gliosarcoma of Brain
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For patients age ≥ 18: Able and willing to provide written
  2. For patients aged 13-17: Parent/guardian of adolescent patient must have the ability to provide written informed consent. Adolescent patients must have the ability to provide written informed assent.
  3. Stated willingness to comply with all trial procedures and availability for the duration of the trial
  4. confirmed diagnosis of World Health Organization Grade IV high-grade glioma. Eligible diagnoses include: Glioblastoma (IDH-wildtype), Gliosarcoma, Diffuse Midline Glioma (H3 K27-altered), diffuse hemispheric glioma (H3 G34-mutant), diffuse pediatric-type high-grade glioma (H3 and IDH-wildtype), Astrocytoma IDH-mutant (Grade 4)
  5. Previous treatment with at least radiotherapy (and temozolomide in the case of glioblastoma or astrocytoma IDH-mutant (grade 4))
  6. Documented recurrence by diagnostic or contrast-enhanced magnetic resonance imaging (MRI) per RANO 2.0 criteria
  7. At least one per RANO 2.0 meeting the following criteria: Contrast-enhancing or non-enhancing lesions with clearly defined margins by MRI Scan, with both perpendicular diameters on a single slice of at least 10 mm, visible on two or more slices that are preferably, at most, 3 mm apart with 0-mm interslice gap.
  8. Age ≥ 13
  9. (ECOG) performance status of 0-2 (age ≥ 16) or Lansky of ≥ 60 (age \<16)
  10. Disease status confirmed with baseline imaging performed within 28 days of Day 1 of trial treatment. Patients with extracranial or will be excluded (see Section 5.2)
  11. Subjects must be on a stable or decreasing dose of for at least 7 days before enrollment
  12. Patients must have organ and marrow function as defined below:

    Eligibility Guidelines of Organ and Marrow Function Hematologic (ANC) ≥ 1.5 x 109/L ≥ 9.0 g/dL ≥ 75 x 109/L and PTT ≤ 1.5 X Hepatic Total ≤ 1.5 X ULN (except subjects with known Gilbert syndrome, who can have total bilirubin \< 3.0 mg/dL and ALT ≤ 3.0 X ULN Renal Creatinine OR Calculated OR 24-hour urine creatinine clearance ≤ 2 X ULN

    • 50 mL/min
    • 50 ml/min
  13. Women of (WOCBP) must have a negative serum or urine pregnancy test within 24 hours of starting therapy
  14. WOCBP must agree to follow instructions for methods of
  15. Men who are sexually active with WOCBP must agree to follow instructions for methods of contraception
  16. Investigators will counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and implications of an unexpected pregnancy. At a minimum subjects must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective: starting at ICF or first dose and continuing 6 months after last dose of trial treatment:

    Highly effective methods of contraception Male condoms with spermicide Hormonal methods including combined oral contraceptive pills, vaginal ring, injectables, implants, and intrauterine devices (IUD) Non-hormonal IUD Tubal ligation Vasectomy Complete Abstinence

    Less effective methods of contraception Diaphragm with spermicide Cervical cap with spermicide Vaginal sponge Male condom without spermicide Progestin only pills Female condom

  17. An interval of ≥ 2 weeks from major surgery
  18. An interval of ≥ 4 weeks from chemotherapy, radiotherapy, or other agents

Exclusion criteria

EXCLUSION CRITERIA

  1. Presence of extracranial or
  2. Patients with diffuse intrinsic pontine glioma, defined as tumors with a pontine epicenter and diffuse involvement of the pons
  3. Patients must not have active disease that has required systemic treatment in the past 2 years (e.g. use of disease modifying agents, , or drugs)
  4. Prior azacitidine for the treatment of cancer (prior administration of nivolumab or other is allowed)
  5. Subjects with major medical, neurologic, or psychiatric condition who are judged to be unable to fully comply with trial therapy or assessments
  6. Positive test for or C virus indicating acute or chronic infection, given the risk of reactivation with checkpoint inhibition
  7. Known history of testing positive for or known acquired immunodeficiency syndrome (AIDS), due to the unknown effects of HIV on the immune response to intrathecal azacitidine and nivolumab
  8. Patients with a history of pneumonitis
  9. Evidence of active infection requiring treatment with IV antibiotics ≤ 7 days prior to initiation of trial therapy.
  10. History of allergy to trial drug components
  11. Prisoners or subjects involuntarily incarcerated

Patients of all genders, races, and ethnicities are invited to participate.

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Treatment (IT nivolumab + IT azacitidine)

    Patients will receive intrathecal azacitidine on day 1, 8, and 22 of cycle 1 (34 day cycle). Intrathecal nivolumab will be given at a flat dose of 40 mg on day 8 and 22. Each subsequent cycle will be 28 days with intrathecal azacitidine and intrathecal nivolumab given on days 1 and 15. Intrathecal azacitidine will be dose-escalated with 4 dose levels (5, 10, 20, 40 mg) using a 3+3 design. Patients may continue on study in the absence of disease progression or unacceptable toxicity. Patients will have CSF and blood specimen collection on days 1 and 8 of cycle 1, and then day 1 of every-other cycle starting with cycle 2. Patients will undergo MRI at baseline, then every 8 weeks (e.g. after cycle 3, cycle 5, etc…).

    Drug: Nivolumab · Drug: Azacitidine (AZA) · Procedure: lumbar puncture · Diagnostic Test: MRI Contrast

Interventions

  • Intrathecal nivolumab will be given at a flat dose of 40 mg

  • DrugAzacitidineStudies of AzacitidineAzacitidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intrathecal azacitidine will be dose-escalated with 4 dose levels (5, 10, 20, 40 mg) using a 3+3 design.

  • Procedurelumbar puncture

    Lumbar puncture for intrathecal delivery and collection of CSF

  • Diagnostic testMRI Contrast

    MRI Brain and full Spine (with and without contrast) will be performed prior to enrollment. During trial therapy, MRI Brain (with and without contrast) will be performed after cycle 1 and after that every 8 weeks (e.g. after cycle 3, cycle 5, etc…)

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Adverse events will be graded by the Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: 24 months

  2. Maximum tolerated dose (MTD) of intrathecal azacitidine in combination with intrathecal nivolumab

    The MTD will be established using a 3+3 design.

    Time frame: 24 months

  3. Overall Response Rate (Expansion Cohort)

    The primary objective of the expansion cohort is to obtain a preliminary estimate of the overall response rate (ORR). ORR will be defined as the proportion of patients with a complete response (CR) or partial response (PR) according to Response Assessment in Neuro-Oncology (RANO) 2.0 criteria

    Time frame: 24 months

Secondary outcomes

  1. To estiamte the duration of response (DOR)

    DOR will be defined as the time from first documented complete response (CR) or partial response (PR) to progressive disease (PD) according to RANO 2.0 criteria

    Time frame: 24 months

  2. To estimate progression-free survival

    PFS will be defined as the time from trial treatment initiation to first documented progression or death due to any cause.

    Time frame: 24 months

  3. To estimate overall survival

    OS will be defined as the time from trial treatment initiation to death due to any cause.

    Time frame: 24 months

  4. To assess biomarkers for immunologic and epigenetic effects of therapy

    Changes in CSF and blood immunological profiling by flow cytometry, cytokine/chemokine analysis. Changes in circulating tumor DNA (ctDNA) analysis in CSF

    Time frame: 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Study protocol and Informed Consent Form (ICF)

Supporting information: Study protocol, Informed consent form

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2028, 33 months after the start.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 33 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Mar 2027 → Mar 2028 and completion Mar 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Mar 26, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Mar 2028was Mar 2027
CompletionEst.
Mar 2028was Mar 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2027→Mar 2028
Oct 27, 2026
Study completion
Mar 2027→Mar 2028
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Mar 2027→Mar 2028
    Study completion Mar 2027→Mar 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06896110
Lead sponsor
Andrew P. Groves
Responsible party
Andrew P. Groves (Clinical Assistant Professor, University of Iowa) — Sponsor-investigator
First posted
Mar 26, 2025
Start date
Jun 5, 2025
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Azacitidine

Start the discussion